Clonal differences underlie variable responses to sequential and prolonged treatment
暂无分享,去创建一个
Sydney M. Shaffer | S. Shaffer | Dylan L. Schaff | Robert J. Vander Velde | Aria J. Fasse | Phoebe E. White
[1] Sydney M. Shaffer,et al. Disrupting cellular memory to overcome drug resistance , 2022, bioRxiv.
[2] Gustavo S. França,et al. Drug-induced adaptation along a resistance continuum in cancer cells , 2022, bioRxiv.
[3] A. Marusyk,et al. Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm. , 2022, Trends in cancer.
[4] A. Raj,et al. Pre-determined diversity in resistant fates emerges from homogenous cells after anti-cancer drug treatment , 2021, bioRxiv.
[5] Jun Yao,et al. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming , 2021, Oncogenesis.
[6] Xiaochen Bo,et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.
[7] R. Mathijssen,et al. Cross-resistance and drug sequence in prostate cancer. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[8] Raphael Gottardo,et al. Integrated analysis of multimodal single-cell data , 2020, Cell.
[9] S. Dawson,et al. Non-genetic mechanisms of therapeutic resistance in cancer , 2020, Nature Reviews Cancer.
[10] S. Rose-John. Interleukin-6 signalling in health and disease , 2020, F1000Research.
[11] G. Mills,et al. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma , 2020, Clinical Cancer Research.
[12] P. Rutkowski,et al. Targeted Therapy in Melanoma and Mechanisms of Resistance , 2020, International journal of molecular sciences.
[13] Jacob G. Scott,et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures , 2020, Nature Communications.
[14] Sydney M. Shaffer,et al. Variability within rare cell states enables multiple paths towards drug resistance , 2020, Nature Biotechnology.
[15] Younan Chen,et al. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells. , 2020, Experimental cell research.
[16] Gennady Korotkevich,et al. Fast gene set enrichment analysis , 2019, bioRxiv.
[17] C. Cho,et al. Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy , 2019, Front. Oncol..
[18] Tengyu Ko,et al. Genome‐wide screening identifies novel genes and biological processes implicated in cisplatin resistance , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] A. Sartore-Bianchi,et al. Treatment sequencing in metastatic colorectal cancer. , 2019, European journal of cancer.
[20] J. Simon,et al. Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment , 2019, Scientific Reports.
[21] M. Yousefi,et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[22] Samantha A. Morris,et al. Single-cell mapping of lineage and identity in direct reprogramming , 2018, Nature.
[23] Allon M. Klein,et al. Lineage tracing on transcriptional landscapes links state to fate during differentiation , 2018, Science.
[24] Sydney M. Shaffer,et al. Memory Sequencing Reveals Heritable Single-Cell Gene Expression Programs Associated with Distinct Cellular Behaviors , 2018, Cell.
[25] Geoff S. Higgins,et al. Oxidative Phosphorylation as an Emerging Target in Cancer Therapy , 2018, Clinical Cancer Research.
[26] Sydney M. Shaffer,et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.
[27] N. McGranahan,et al. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.
[28] Wolfgang Weninger,et al. Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. , 2016, The Journal of investigative dermatology.
[29] N. Dhomen,et al. Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. , 2016, Cancer discovery.
[30] Shuiping Gao,et al. Down-Regulation of NDUFB9 Promotes Breast Cancer Cell Proliferation, Metastasis by Mediating Mitochondrial Metabolism , 2015, PloS one.
[31] P. Rutkowski,et al. Trametinib: a MEK inhibitor for management of metastatic melanoma , 2015, OncoTargets and therapy.
[32] V. Sondak,et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells , 2015, Oncogene.
[33] H P Soyer,et al. A stress-induced early innate response causes multidrug tolerance in melanoma , 2014, Oncogene.
[34] R. Hay,et al. E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin. , 2014, Cancer research.
[35] O. Sartor,et al. Treatment sequencing in metastatic castrate-resistant prostate cancer , 2014, Asian journal of andrology.
[36] Christopher J. Ott,et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia , 2014, Nature Genetics.
[37] D. Mukherji,et al. Sequencing of treatment in metastatic colorectal cancer: where to fit the target. , 2014, World journal of gastroenterology.
[38] R. Dummer,et al. Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. , 2013, The Journal of investigative dermatology.
[39] P. Gimotty,et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.
[40] G. Long,et al. Dabrafenib and its potential for the treatment of metastatic melanoma , 2012, Drug design, development and therapy.
[41] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.
[42] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[43] K. Pienta,et al. Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer , 2012, Molecular Cancer Research.
[44] P. Yotnda,et al. Induction and testing of hypoxia in cell culture. , 2011, Journal of visualized experiments : JoVE.
[45] Jian Wu,et al. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. , 2011, Cytokine.
[46] Alexander Roesch,et al. A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.
[47] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[48] P. Sorger,et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.
[49] N. Pavlakis,et al. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. , 2007, Cancer treatment reviews.
[50] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[51] D. Mottet,et al. CoCl2, a Chemical Inducer of Hypoxia‐Inducible Factor‐1, and Hypoxia Reduce Apoptotic Cell Death in Hepatoma Cell Line HepG2 , 2002, Annals of the New York Academy of Sciences.
[52] A. Fojo,et al. Multidrug resistance in ovarian cancer , 1987, Cancer.
[53] S. Lippard,et al. Structural aspects of platinum anticancer drug interactions with DNA , 1987 .
[54] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[55] R. Sullivan,et al. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition , 2017, Journal of immunotherapy.
[56] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.